26 Jul Rescinding of 2002 call-up notice for CAMs
Medicines and related substances ACT, 1965 (ACT 101 of 1965) ...
Rescinding of 2002 call-up notice for CAMs
26 Jul GG40480 Medical Device Regulations
Regulations relating to medical devices and in vitro Diagnostic Medical Devices ...
26 Jul SAHPRA Annual Performance Plan (APP) 2019-2020
Annual Performance plan for the fiscal year 2019/20 ...
26 Jul Medicines Control Council alerts the public of the risks and harm associated with the inappropriate and non-prescribed use of testosterone-containing medicines
Medicines Control Council alerts the public of the risks and harm associated with the inappropriate and non-prescribed use of testosterone-containing medicines ...
26 Jul ICH Press Release Osaka Japan 9-10 November 2016
First new regulatory Members of ICH, key global good clinical practice guideline revisions agreed The International Council for Harmonisation (ICH) met in Osaka, Japan on 5-10 November 2016. ...
19 Jul APPOINTMENT OF THE SAHPRA BOARD
The Minister of Health, Dr Aaron Motsoaledi, has appointed members of the South African Health Products Regulatory Authority (SAHPRA) Board. SAHPRA replaces the Medicines Control Council (MCC). The scope of the new Authority has expanded to include not only medicines, but also medical devices including...
19 Jul MEDICINES CONTROL COUNCIL
In the light of recent media reports, the Medicines Control Council wishes to clarify the current framework for access to cannabis for medicinal purposes in South Africa. ...
10 May WHO OR WHAT IS SAHPRA
10 May 2019 SAHPRA is the South African Health Products Regulatory Authority. It is a Section 3A public entity that was formed by the South African government to oversee the regulation of health products which includes medicines, medical devices, in-vitro diagnostic tests and devices, radiation emitting...
01 Jun MSA COUGH AND COLD MEDICINES
The Medicines Control Council (MCC) of South Africa wishes to alert healthcare professionals that the use of oral cough and cold medicines containing certain ingredients is now contraindicated in children under the age of two years. This decision is in line with international recommendations regarding the...
24 Jun MSA atypical antipsychotics
The Medicines Control Council wishes to inform prescribers of increased risks of cerebrovascular adverse events (including strokes and transient ischaemic attacks) and mortality associated with the use of atypical antipsychotics in elderly patients with dementia. The atypical antipsychotics to which this medicine safety alert refers...